reglab/housing_qa huggingface dataset:
16 DE Code § 808A. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8A. Universal Newborn and Infant Hearing Screening, Tracking, and Intervention|§ 808A. Early Hearing Detection and Intervention (EHDI) Advisory Board.

§ 808A. Early Hearing Detection and Intervention (EHDI) Advisory Board. There shall be established an Early Hearing Detection and Intervention Advisory Board (“Board”) that will advise the Secretary on issues relating to the newborn hearing evaluation, intervention, treatment, and follow-up care for infants and children with hearing loss. Members shall be appointed by the Governor and serve 3-year terms that are renewable. The Board shall have 12 members. (1) The Department shall provide administrative support services required for the Board. Members shall receive no compensation for their services as members. (2) The Board shall act by majority vote and as required by this State's Administrative Procedures Act [Chapter 101 of Title 29]. The Board shall have the authority to adopt rules to implement this chapter. (3) The Board membership shall consist of 1 of each the following:  Audiologist; Speech-language pathologist; Pediatrician/neonatologist; Otolaryngologist; Neonatal nurse; The Secretary of the Department of Health and Social Services or designee; An adult who is deaf or hard of hearing; Parent of a child with a hearing loss; Teacher of children with hearing loss; A representative from the designated agency responsible for the Individuals with Disabilities Education Act (IDEA) Part C [20 U.S.C. § 1431 et seq.]; A representative from the Department of Education Early Childhood Workgroup; and A representative from the Statewide Programs for Deaf and Hard of Hearing.78 Del. Laws, c. 389, §  1;
16 DE Code § 809A. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8A. Universal Newborn and Infant Hearing Screening, Tracking, and Intervention|§ 809A. Civil and criminal immunity and penalties.

§ 809A. Civil and criminal immunity and penalties. (a) No physician shall be civilly or criminally liable for failure to conduct hearing screening testing. (b) No physician or hospital acting in compliance with this chapter shall be civilly or criminally liable for any acts taken in conformity herewith, including without limitation furnishing information required to be furnished hereunder. (c) A hospital that has not established or implemented an UNHS program in accordance with this chapter shall be subject to sanction by the Division of Public Health as provided by law for licensure violations. 75 Del. Laws, c. 116, §  1;  78 Del. Laws, c. 389, §  1;
16 DE Code § 810A. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8A. Universal Newborn and Infant Hearing Screening, Tracking, and Intervention|§ 810A. Confidentiality.

§ 810A. Confidentiality. The Division of Public Health and all other persons to whom data is submitted in accordance with this chapter shall keep such information confidential. No publication or disclosure of information shall be made except in the form of statistical or other studies which do not identify individuals, except as specifically consented to in writing the by the parent or parents of a tested child. 75 Del. Laws, c. 116, §  1;  78 Del. Laws, c. 389, §  1;
16 DE Code § 811A. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8A. Universal Newborn and Infant Hearing Screening, Tracking, and Intervention|§ 811A. Delivery of policy.

§ 811A. Delivery of policy. If a health insurance policy provides coverage or benefits to a resident of this State, it shall be deemed to be delivered in this State within the meaning of this chapter, regardless of whether the health-care insurer issuing or delivering said policy is located inside or outside of the State. 75 Del. Laws, c. 116, §  1;  78 Del. Laws, c. 389, §  1;
16 DE Code § 801B. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8B. Down Syndrome Information|§ 801B. Provision of information relating to Down Syndrome.

§ 801B. Provision of information relating to Down Syndrome. (a) For the purposes of this section, the term “Down Syndrome” shall mean a chromosomal condition caused by an error in cell division that results in the presence of an extra whole or partial copy of chromosome 21. A hospital, as that term is defined in § 803A of this title, physician, health-care provider, nurse midwife or genetic counselor who renders prenatal care, postnatal care or genetic counseling shall, upon receipt of a positive test result from a test for Down Syndrome, provide the expectant or new parent with information provided by the department under subsection (b) of this section. (b) The Department shall make available to a person who renders prenatal care, postnatal care or genetic counseling to parents who receive a prenatal or postnatal diagnosis of Down Syndrome the following:  (1) Up-to-date evidence-based, written information about Down Syndrome that has been reviewed by medical experts and national Down Syndrome organizations; provided, however, that the written information provided shall include physical, developmental, educational and psychosocial outcomes, life expectancy, clinical course and intellectual and functional development and treatment options; and (2) Contact information regarding first call programs and support services, including information hotlines specific to Down Syndrome, resource centers or clearinghouses, national and local Down Syndrome organizations, and other educational and support programs. The Department may also make such information available to any other person who has received a positive test result from a test for Down Syndrome. (c) The Department shall meet annually with representatives of the Down Syndrome Association of Delaware to ensure the information made available by the department is up to date. (d) The Department shall submit a report by January 31 of each year to the Co-Chairs of the Joint Finance Committee detailing the persons to whom the information required by subsection (b) of this section has been distributed. 79 Del. Laws, c. 218, §  1;
16 DE Code § 801C. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8C. Screening of Newborn Infants for Metabolic, Hematologic, Endocrinologic, Immunologic, and Certain Structural Disorders|§ 801C. Short title.

§ 801C. Short title. This chapter shall be known and may be cited as the “Newborn Screening Program.” 80 Del. Laws, c. 96, §  1;
16 DE Code § 802C. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8C. Screening of Newborn Infants for Metabolic, Hematologic, Endocrinologic, Immunologic, and Certain Structural Disorders|§ 802C. Definitions.

§ 802C. Definitions. (a) “Blood specimen for metabolic, hematologic, endocrinologic, and immunologic disorders” means a dried blood spot on a special filter paper utilized for screening (not diagnostic) tests to establish the likely presence of metabolic, hematologic, endocrinologic, or immunologic disorders. (b) “Certain structural disorders” includes critical congenital heart defects and other structural disorders. (c) “Endocrinologic disorder” means the absence or deficiency of a hormone resulting in interference with normal health, growth or development. These disorders include, but are not limited to congenital hypothyroidism and congenital adrenal hyperplasia. (d) “Hematologic disorder” means, a condition in which a variation in 1 or more of the hemoglobin structural genes or in 1 or more of the genes involved in hemoglobin synthesis produces a variation in hemoglobin structure or synthesis, which results in variation in hemoglobin function. These disorders include, but are not limited to, sickle cell anemia, sickle beta thalassemia, beta thalassemia, alpha thalassemia, hemoglobin C disease and other clinically important variations in hemoglobin structure or synthesis. (e) “Immunologic disorder” means, a condition in which a variation in the quantity or function of white blood cells results in deficiency of immune function. These disorders include, but are not limited to, severe combined immunodeficiency disorder. (f) “Kit” means any or all parts of the combined materials, laboratory filter paper specimen forms, Newborn Screening Program brochure, and/or other components provided by the state Newborn Screening Program for the purposes of collection of the blood spot specimen and for submission of the blood spot specimen for laboratory screening. (g) “Metabolic disorder” means a disorder caused by a genetic alteration, which results in a defect in the structure or function of a specific enzyme or other protein. These disorders include, but are not limited to, phenylketonuria (PKU), galactosemia, maple syrup urine disease (MSUD), and medium chain acyl-CoA dehydrogenase (MCAD) deficiency. (h) “Newborn infant” means any infant born in the State who is under 4 weeks of age. (i) The “Newborn Screening Advisory Committee” means a committee, established through this chapter, convened to provide advice and guidance to the Director of Public Health. (j) “Satisfactory specimen” means a blood spot specimen on which an accurate laboratory analysis for the various disorders can be performed. 80 Del. Laws, c. 96, §  1;
16 DE Code § 803C. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8C. Screening of Newborn Infants for Metabolic, Hematologic, Endocrinologic, Immunologic, and Certain Structural Disorders|§ 803C. Newborn Screening Advisory Committee.

§ 803C. Newborn Screening Advisory Committee. There shall be established Newborn Screening Advisory Committee (“Committee”) that will advise the Director of the Division of Public Health on issues relating to the newborn screening program, including intervention, treatment, and follow-up care for infants and children with metabolic, hematologic, endocrinologic, immunologic and certain structural disorders. Members shall be appointed by the Governor and serve 3-year terms that are renewable. The Committee shall have 13 members. (1) The Department of Health and Social Services shall provide administrative support services required for the Committee. Members shall receive no compensation for their services as members. (2) The Committee shall act by majority vote and as required by this State's Administrative Procedures Act, Chapter 101 of Title 29. The Committee shall meet at least 3 times annually. (3) The Committee membership shall consist of: 3 individuals, or parents of individuals, affected by disorders identified by the screening panel; an ethicist; an attorney not employed by the State; 3 pediatric physicians; the Medical Director for the Division of Public Health, or his or her designee; the Laboratory Director for the Division of Public Health, or his or her designee; a representative from the Department of Services for Children Youth and their Families; the Chair of the Midwifery Advisory Council, or his or her designee; and a member of the public. (4) The Committee shall elect a Chairperson to serve for at least 1 year from those members appointed by the Governor. A majority of the membership of the Committee shall constitute a quorum to transact its business.80 Del. Laws, c. 96, §  1;  70 Del. Laws, c. 186, §  1;
16 DE Code § 804C. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8C. Screening of Newborn Infants for Metabolic, Hematologic, Endocrinologic, Immunologic, and Certain Structural Disorders|§ 804C. Newborn Screening Program.

§ 804C. Newborn Screening Program. (a) The Department of Health and Social Services shall adopt rules and regulations under and pursuant to this State's Administrative Procedures Act, Chapter 101 of Title 29, to carry out the objectives of this chapter. All prior regulations and rules promulgated by the Delaware Division of Public Health in regard to the screening of newborn infants for diseases shall remain in full force and effect until amended or repealed by the Department. (b) All hospitals, birthing centers and other birth attendants shall obtain a satisfactory specimen within 24 to 48 hours of age and shall perform, or arrange for, screening for critical congenital heart defects. (c) The Division of Public Health shall provide results to the physician on record. (d) The Director of the Division of Public Health, with advice from the Committee, will determine which disorders shall be on the screening panel. (e) Blood specimens for metabolic, hematologic, endocrinologic, and immunologic disorders will be destroyed after screening and testing is complete. Screening and testing includes confirmation of any diagnosis. (f) Records obtained from screenings will be retained by the Division of Public Health. (g) Fees. — (1) (1) The Newborn Screening Program shall bill the birth facility or individual attending the birth for services provided for each newborn screened under these regulations including but not limited to, the cost of the kits for collection of specimens, the laboratory fee for analysis, and administrative costs. The amount billed will be determined by the Director of the Division of Public Health in consultation with the Advisory Committee and the program staff. The fee will be determined in July of each year based on the cost of the program. All fees collected as a result of billing are hereby appropriated to, and shall be retained by, the Newborn Screening Program to defray operating expenses associated with this chapter, operation of the Program, and programming to ensure the optimal health and development across the lifespan of the maternal and child health population. (2) No Delaware newborn shall be denied testing for hereditary disorders because of inability of the newborn's parent or legal guardian to pay the fee.80 Del. Laws, c. 96, §  1;  83 Del. Laws, c. 167, § 1;
16 DE Code § 805C. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8C. Screening of Newborn Infants for Metabolic, Hematologic, Endocrinologic, Immunologic, and Certain Structural Disorders|§ 805C. Parental options.

§ 805C. Parental options. (a) All newborns in Delaware shall have a satisfactory specimen taken within 24 to 48 hours of age and shall be screened for metabolic, hematologic, endocrinologic, immunologic and certain structural disorders. Parents may elect not to participate in any of the following:  (1) Screening to be performed; (2) The blood spot to be stored following testing; and/or (3) The results of the screen to be securely shared electronically through a health information exchange so that health-care providers can appropriately access information. (b) The informed consent process shall assure that the parent or guardian who elects that a newborn shall not be tested understands the consequences of such a decision, including the inability to prevent developmental delay and death. Language conveying such information shall be recommended by the Committee for approval by the Division Director. (c) There will be no research utilizing the stored blood specimens or the stored data without parental consent, except for population-based studies in which all identifying information is removed. 80 Del. Laws, c. 96, §  1;  83 Del. Laws, c. 167, § 1;
16 DE Code § 806C. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8C. Screening of Newborn Infants for Metabolic, Hematologic, Endocrinologic, Immunologic, and Certain Structural Disorders|§ 806C. Confidentiality.

§ 806C. Confidentiality. (a) No person may disclose or be compelled to disclose the identity of any person upon whom a blood specimen for metabolic, hematologic, endocrinologic, immunologic and certain structural disorders screen is performed, or the results of such test in a manner which permits identification of the subject of the test, except to the following person:  (1) The subject of the test or the subject's legal guardian. (2) Any person who secures a legally effective release of test results executed by the subject of the test or the subject's legal guardian. (3) For purposes of diagnosis, treatment or follow-up. (4) As authorized by court order. (5) To a medical examiner authorized to conduct an autopsy on a child or an inquest on the death of a child. (6) Health facility staff committees or accreditation or oversight review organizations which are conducting program monitoring, program evaluation or service reviews, including the Child Death Review Commission conducting reviews pursuant to Title 31. (7) Individuals who have access to an electronic medical record (EMR), in which the information is retained pursuant to § 1203(a)(6) of this title, or a health information exchange. (8) Pursuant to Chapter 9 of this title as it relates to investigation of child abuse. (b) No person to whom the results of a blood specimen for metabolic, hematologic, endocrinologic, immunologic and certain structural disorders screen have been disclosed pursuant to subsection (a) of this section shall disclose the test results to another person except as authorized by subsection (a) of this section. (c) The provisions in this section shall not interfere with the transmission of information as may be necessary to obtain third-party payment for medical care related to a metabolic, hematologic, endocrinologic, immunologic, or certain structural disorders or with the documentation of cause of death on death certificates. 80 Del. Laws, c. 96, §  1;  80 Del. Laws, c. 187, §  16;  83 Del. Laws, c. 167, § 1;
16 DE Code § 801D. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8D. Maternal Mental Health|§ 801D. Policy.

§ 801D. Policy. The maternal mental health-care policy of this State shall serve to increase the likelihood that a woman who has given birth and demonstrates symptoms of maternal depression will receive the necessary mental health treatment. The goal of this policy is to provide sufficient resources of information and support, including patient screening soon after childbirth, for women with maternal depression to decrease child abuse or neglect and the need for inpatient treatment. 80 Del. Laws, c. 293, §  1;  70 Del. Laws, c. 186, §  1;
16 DE Code § 802D. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8D. Maternal Mental Health|§ 802D. Definitions.

§ 802D. Definitions. As used in this chapter:  (1) “Maternal depression” means a wide range of emotional and psychological reactions that a woman may experience during pregnancy or after childbirth, as the range of reactions is defined in the Diagnostic and Statistical Manual of Mental Disorders. The reactions may include: feelings of despair or extreme guilt; prolonged sadness; lack of energy; difficulty concentrating; fatigue; extreme changes in appetite; or thoughts of suicide or harming the baby. (2) “Maternal health-care provider” means a physician, midwife, advanced practice registered nurse, registered nurse, physician assistant, or other health-care practitioner acting within his or her lawful scope of practice while attending a woman who presents with signs of maternal depression.80 Del. Laws, c. 293, §  1;  70 Del. Laws, c. 186, §  1;
16 DE Code § 803D. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8D. Maternal Mental Health|§ 803D. Maternal depression materials and information.

§ 803D. Maternal depression materials and information. (a) The Department shall develop written materials and information about maternal depression. (1) The materials and information shall include the symptoms and methods of coping with maternal depression and treatment resources. (2) The Department shall periodically review the materials and information to determine their effectiveness and ensure they reflect the most up-to-date and accurate information. (3) The Department shall post on its website the materials and information. (4) The Department may make available or distribute the materials and information in physical form upon request. (b) Maternal health-care providers shall do all of the following:  (1) Provide the materials and information developed under subsection (a) of this section to any woman who presents with signs of maternal depression. (2) Encourage any woman who presents with signs of maternal depression to share the materials and information with her baby's family members or caregivers and her family members and caregivers. (c) Hospitals and other health-care facilities shall do all of the following:  (1) Provide, upon discharge, the materials and information developed under subsection (a) of this section to any woman who presents with signs of maternal depression. (2) Encourage any woman who presents with signs of maternal depression to share the materials and information with her baby's family members or caregivers and her family members and caregivers.  (d) The Behavioral Health Commission shall assess and recommend improvements to the materials and information developed under subsection (a) of this section, in an effort to create greater statewide resources. 80 Del. Laws, c. 293, §  1;  70 Del. Laws, c. 186, §  1;
16 DE Code § 804D. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8D. Maternal Mental Health|§ 804D. Maternal depression screening.

§ 804D. Maternal depression screening. Maternal health-care providers shall begin evaluations and take action when they recognize symptoms of maternal depression in a woman or family, including when care for a baby suffers or other symptoms as defined in the Diagnostic and Statistical Manual of Mental Disorders. 80 Del. Laws, c. 293, §  1;  70 Del. Laws, c. 186, §  1;
16 DE Code § 805D. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 8D. Maternal Mental Health|§ 805D. Enforcement.

§ 805D. Enforcement. The Department may develop regulations governing compliance under this chapter. 80 Del. Laws, c. 293, §  1;
16 DE Code § 901B. (2021)
2021 Delaware Code|Title 16 - Health and Safety|Chapter 9B. Infants With Prenatal Substance Exposure.|§ 901B. Purpose.

§ 901B. Purpose. The child welfare policy of this State shall serve to advance the best interests and secure the safety and well-being of an infant with prenatal substance exposure, while preserving the family unit whenever the safety of the infant is not jeopardized. To further this policy, this chapter:  (1) Requires that notifications of infants with prenatal substance exposure be made to the Division by the health-care provider involved in the delivery or care of the infant. (2) Requires a coordinated, service-integrated response by various agencies in this State's health and child welfare systems to work together to ensure the safety and well-being of infants with prenatal substance exposure by developing, implementing, and monitoring a Plan of Safe Care that addresses the health and substance use treatment needs of the infant and affected family or caregiver.81 Del. Laws, c. 257, § 1;